Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, CH-3001 Bern, Switzerland; Graduate School of Cellular and Biomedical Sciences, University of Bern, Freiestrasse 1, CH-3012 Bern, Switzerland.
Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, CH-3001 Bern, Switzerland.
J Glob Antimicrob Resist. 2017 Mar;8:179-185. doi: 10.1016/j.jgar.2016.12.013. Epub 2017 Feb 21.
Bacteriophages may represent a therapeutic alternative to treat infections caused by multidrug-resistant (MDR) pathogens. However, studies analysing their activity against MDR Enterobacteriaceae are limited.
The in vitro lytic activity of three commercial bacteriophage cocktails (PYO, INTESTI and Septaphage) was evaluated against 70 Escherichia coli and 31 Proteus spp. of human and non-human origin. Isolates were characterised by phenotypic and genotypic methods and included 82 MDR strains [44 extended-spectrum-β-lactamase (ESBL)-producers (18 CTX-M-15-like, including ST131/ST648 E. coli); 27 plasmid-mediated AmpC β-lactamase (pAmpC)-producers (23 CMY-2-like, including ST131 E. coli); 3 ESBL+pAmpC-producers; and 8 carbapenemase-producers]. Phage susceptibility was determined by the spot test.
E. coli susceptibility to PYO, INTESTI and Septaphage was 61%, 67% and 9%, whereas that of Proteus spp. was 29%, 39% and 19%, respectively. For the subgroup of ESBL-producing E. coli/Proteus spp., the following susceptibility rates were recorded: PYO, 57%; INTESTI, 59%; and Septaphage, 11%. With regard to pAmpC-producers, 59%, 70% and 11% were susceptible to PYO, INTESTI and Septaphage, respectively. Five of eight carbapenemase-producers and three of four colistin-resistant E. coli were susceptible to PYO and INTESTI.
This is the first study analysing the activity of the above three cocktails against well-characterised MDR E. coli and Proteus spp. The overall narrow spectrum of activity observed could be related to the absence of specific bacteriophages targeting these contemporary MDR strains that are spreading in different settings. Therefore, bacteriophages targeting emerging MDR pathogens need to be isolated and integrated in such biopreparations.
噬菌体可能代表一种治疗多药耐药（MDR）病原体感染的治疗选择。然而，分析其对 MDR 肠杆菌科的活性的研究有限。
评估了三种商业噬菌体鸡尾酒（PYO、INTESTI 和 Septaphage）对 70 株人源和非人类来源的大肠杆菌和 31 株变形菌的体外溶菌活性。通过表型和基因型方法对分离株进行了特征描述，包括 82 株 MDR 菌株[44 株扩展谱β-内酰胺酶（ESBL）-生产者（18 株 CTX-M-15 样，包括 ST131/ST648 大肠杆菌；27 株质粒介导的 AmpCβ-内酰胺酶（pAmpC）-生产者（23 株 CMY-2 样，包括 ST131 大肠杆菌；3 株 ESBL+pAmpC-生产者；和 8 株碳青霉烯酶-生产者）]。噬菌体敏感性通过点试验确定。
大肠杆菌对 PYO、INTESTI 和 Septaphage 的敏感性分别为 61%、67%和 9%，而变形菌的敏感性分别为 29%、39%和 19%。对于 ESBL 产生的大肠杆菌/变形菌亚组，记录了以下敏感性率：PYO，57%；INTESTI，59%；和 Septaphage，11%。对于 pAmpC-生产者，PYO、INTESTI 和 Septaphage 的敏感性分别为 59%、70%和 11%。8 株碳青霉烯酶生产者中的 5 株和 4 株耐多粘菌素的大肠杆菌对 PYO 和 INTESTI 敏感。
这是第一项分析上述三种鸡尾酒对经过充分特征描述的 MDR 大肠杆菌和变形菌的活性的研究。观察到的窄谱活性可能与缺乏针对这些在不同环境中传播的现代 MDR 菌株的特定噬菌体有关。因此，需要分离和整合针对新兴 MDR 病原体的噬菌体到这些生物制剂中。
